Clinical Trial: A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents

U.S., Oct. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07890701) titled 'A Single-Arm,Multicenter Phase, Phase II Clinical Trial of Adebrelimab Combined With Trametinib in the Treatment of Refractory Recurrent Langerhans Cell Histiocytosis in Children and Adolescents' on Oct. 16.

Brief Summary: Based on clinical observation data from two previously enrolled cases, the adezbelimab combined with trametinib regimen showed good safety in pediatric refractory relapsed LCH, with good drug tolerance. Both children benefited clinically from the combination regimen, preliminarily validating the feasibility and effectiveness of this regimen in treating refractory relapsed LCH in children. To systematically validat...